On the Record · Novo Nordisk
Novo Nordisk acquisitions, on the record
The businesses Novo Nordisk bought and sold, as its annual reports describe them, with the cash it reported paying for acquisitions each year and every deal filing since 2016.
Deals its annual reports describe
| Business | Deal | When | Value |
|---|---|---|---|
Biocorp Production S.A.Word for word“The purchase price of the asset acquisition was approximately EUR 154 million.” 20-F for 2023 | acquisition | — | approximately EUR 154 million |
Inversago Pharma Inc.Word for word“The purchase price of the asset acquisition was approximately USD 600 million with additional contingent payments of USD 475 million.” 20-F for 2023 | acquisition | — | approximately USD 600 million |
Ocedurenone asset from KBP Biosciences PTE., Ltd.Word for word“The purchase price of the asset acquisition was USD 800 million with additional contingent payments of USD 500 million.” 20-F for 2023 | agreed acquisition | — | USD 800 million |
three fill-finish sites from Novo Holdings A/S (former Catalent, Inc. fill-finish sites)Word for word“On December 18, 2024, Novo Nordisk acquired three fill-finish sites from Novo Holdings A/S in connection with a transaction where Novo Holdings A/S acquired Catalent, Inc. (“Catalent”), a global contract development and manufacturing organisation.” 20-F for 2024 | acquisition | On December 18, 2024 | — |
Akero Therapeutics Inc.Word for word“Novo Nordisk has acquired all outstanding shares of common stock and common stock equivalents of Akero for 54 USD per share in 1 Product indications described in this Form 20-F are composite summaries of the major indications approved in the product’s principal markets.”” 20-F for 2025 | acquisition | — | 54 USD per share |
three fill-finish sites from Novo Holdings A/SWord for word“The purchase price of the three sites totalled USD 11.7 billion, which was mainly debt-financed.” 20-F for 2025 | acquisition | — | USD 11.7 billion |
Read from Novo Nordisk’s annual reports (20-F for 2025, 20-F for 2024, 20-F for 2023) and the financial data it files with the SEC, as of 2026-02-04. Every quotation is word for word from the filing linked beside it; how these pages are built and checked. The full record is in its company data sheet.